MDVL Sure have, been buying about once a week including a couple this week in the .80s. Their spotRX sites seem to be doing well from what I've seen online and their long term guidance and analyst's estimates are why I've held, with 2022 rev estimate at 39m.
Biggest concern is bottom line estimates aren't expected to be increasing with top line. At the same time, this gives them nice buyout potential as a larger company would be mostly interested in the increasing revenues and more adept at turning a profit.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.